top of page

Leveraging Data for Groundbreaking Discoveries

R&D Philosophy: Data-Informed, Patient-Centric, and Collaborative

Rubix LS’s R&D strategy is built on comprehensive data analysis, patient-centered focus, and collaborative innovation. With access to over 13 million diverse patient records, we are uniquely positioned to address complex healthcare challenges with precision and empathy.

OUR PROCESS

Patient-Centered Research

At Rubix LS, our approach to research is centered around the patient. We believe that by putting the patient first, we can develop treatments that are more effective, safer, and more accessible. Our team works closely with patients, caregivers, and advocacy groups to ensure that our research is focused on the needs of the people we serve. We also collaborate with leading academic institutions, hospitals, and biotech companies to stay at the forefront of medical innovation.

shutterstock_1922200124.jpg

OUr targeted R&D Focus Areas

Targeted R&D Development

  • Special Populations: Our dedication to special populations drives our pursuit to develop effective, culturally sensitive therapies.

  • Personalized Medicine: We focus on tailoring treatments to individual genetic and environmental factors, enhancing treatment efficacy.

Novel Drug Discovery and Biomarker Research

  • AI-Driven Innovation: Utilizing AI, we aim to discover novel drug candidates and develop advanced diagnostic tools.

  • Biomarkers: We are actively researching biomarkers to improve diagnostics and treatment personalization.

Disease Strengths and Development Focus

  • Oncology: We are exploring novel treatments in oncology, with a focus on rare and hard-to-treat cancers.

  • Neurodegenerative Diseases: Our team is working on breakthrough therapies for diseases like Alzheimer's and Parkinson's, aiming to slow progression and improve quality of life.

  • Autoimmune Disorders: Research is underway to develop more effective treatments for autoimmune conditions, with an emphasis on patient-specific factors.

Strategic In-Licensing and Scaling for Impact

We actively seek to in-license promising therapeutic assets, aiming to rapidly scale effective treatments for a wider patient demographic, especially in our key disease focus areas.

Clinical Trials

Our clinical trials are a core part of our R&D efforts, with a focus on ensuring safety and efficacy for our target populations.

This list of Rubix LS trials will be updated periodically.

Collaboration: The Key to Achievement

Rubix LS invites collaboration with experts, researchers, and healthcare professionals to join us in advancing healthcare solutions in our key focus areas.

OUR JOURNEY

2016

RUBIX LS IS FOUNDED

Rubix LS was founded with the mission of conducting research that makes a difference in the lives of patients. From the beginning, we have been committed to putting patients first and developing treatments that meet their needs.

2017

FIRST CLINICAL TRIAL BEGINS

Rubix LS conducts its first clinical trial, testing a new therapy for a rare form of osteonecrotic cancer. The trial results are promising, and the therapy is undergoing continuous studies for approval for use in patients.

shutterstock_1884612574.jpg

Headquarters:

60 Island St, Suite 236

Lawrence, MA 01840

Tel: 978-552-3183

Email: info@rubixls.com

Thanks for subscribing!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • Whatsapp

© 2023 by Rubix LS.

bottom of page